Prolastin Articles
York acquires Rosanto in $4M all share deal
30 April 2007
Viragen and Orphan Int in licensing accord
30 April 2007
J&J's 1st-qtr profits slip 22% on Conor buy
23 April 2007
Merrimack starts Ph II MM-093 enrollment
23 April 2007
Strong Ph II data on Intarcia's omega-INF
23 April 2007
FDA extends review on Wyeth's first-in-class mTOR inhibitor, Torisel, in advanced renal cell carcinoma
16 April 2007
Strong Ph II data for Helix' topical INF-alpha-2b
16 April 2007
Japan
9 April 2007
Algeta listed on the Oslo Stock Exchange
2 April 2007
Norway's Algeta closes $412M offering
2 April 2007
Nutra Pharma unit to publish MS research
2 April 2007
Memory's MEM 3454 start Ph IIa for AD
19 March 2007
Debiopharm validates 0512 as hTNFa vacc
19 March 2007
Norway's Algeta to offer up to 6.1M shares
12 March 2007
EntreMed's Panzem enters liver cancer study
12 March 2007
HanAll to develop Nautilus products in South Korea
12 March 2007
EC clears new Remicade dosing for use in RA
12 March 2007
Nautilus files Belerofon IND
5 March 2007
Abbott
5 March 2007
Alpha Bioligics buys CTM Biotech
5 March 2007
FDA clears RCC label change for Sutent
19 February 2007
Algeta applies to join Oslo Stock Exchange
5 February 2007
OVA system produces human interferon a-2a
29 January 2007
Favorable US patent ruling for Newron
22 January 2007
GenVec gets FDA clearance for EUS TNFerade delivery
22 January 2007
Good Ph III data for Bayer/Onyx Nexavar
15 January 2007
Orphan Australia buys local rights to Viragen's Multiferon
8 January 2007
ImClone initiates IMC-3G3 Ph I trial
8 January 2007
Anti-TNF drug sales to hit $1.3B by 2015
22 December 2006
FDA priority review for Wyeth's Torisel
22 December 2006
Helix last quarter loss improves 7.5%
22 December 2006
Helix initiates Ph II trial of INF cream
18 December 2006
Novartis' Galvus improves glucose control in elderly
18 December 2006
Japan stock market week to Dec 4, 2006
11 December 2006
EHT 0202 upregulates production of beneficial peptide in AD
4 December 2006
Japan's generic drugs market expected to grow 8.8% from 2006 to 2008
27 November 2006
Roche's CERA effective in CKD-based anemia
27 November 2006
Abbott's Humira gets expanded US label
20 November 2006
Strong Ph II data on S-P's golimumab
20 November 2006
Helix completes Ph II trial of topical INF-alpha
20 November 2006
EntreMed's ENMD-1420 active in preclinical trial
20 November 2006
Ablynx and Wyeth sign Nanobody R&D deal
13 November 2006
Kyowa accelerates US drug development
13 November 2006
Memory's MEM 3454 earns milestone from Roche
6 November 2006
S-P announces its AASLD presentation program
6 November 2006
Pfizer's celecoxib to become Japan's first COX-2 inhibitor
30 October 2006
Nautilus Biotech files Belerofon in USA
16 October 2006
Phenoxodiol effective against prostate cancer
16 October 2006
Biogen Idec agrees $200M deal for UCB's oral MS drug
9 October 2006
Calgenex launches OTC psoriasis cream
2 October 2006
VioQuest initiates Ph I/IIa trial of VQD-001
2 October 2006
Chiesi's Curosurf cuts RDS mortality 30%
25 September 2006
Vernalis' losses for 1st-half 2006 down slightly
18 September 2006
Strong Ph II data for Protherics' CytoFab
11 September 2006
Japan stock market week to Aug 28, 2006
4 September 2006
FDA's RHDAC votes in favor of Adeza's Gestiva
4 September 2006
Shire submits Connexyn NDA to US FDA
4 September 2006
Devgen sees good data in trials of oral TNF inhibitors
28 August 2006
Good early efficacy data for Geron's immuno activator
28 August 2006
Alnylam licenses IP to Calando for cancer drug
28 August 2006
Japan stock market week to July 31, 2006
7 August 2006
EC approves Bayer's Nexavar for RCC
31 July 2006
Roche pays Memory $2.3M AD milestone
24 July 2006
Selexis signs SURE deal with Alpha Biologics
17 July 2006
EMEA OKs Kamada's Ph I plan for API
17 July 2006
Newron's safinamide shows promise in PD
3 July 2006
FDA grants Gestiva NDA priority status
19 June 2006
Strong Ph III data for Wyeth's RCC drug
12 June 2006
Positve data on Targeted Genetics' tgAAC95
12 June 2006
Development of B-MS' Pargluva discontinued
29 May 2006
Roche's Copegus/Pegasys "cost effective," study
29 May 2006
FDA OKs Centocor's Remicade in pediatric CD
29 May 2006
Sepragen to acquire assets of Cytobiologics
29 May 2006
Strong RA data for Abbott's Humira + MTX
15 May 2006
AztraZeneca stops the development of Galida
15 May 2006
CHMP thumbs-up for Bayer's Nexavar
8 May 2006
Nautilus: oral protein drugs on the horizon?
1 May 2006
Medarex/MedImmune begin dosing in Ph I MEDI-545 trial
24 April 2006
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
